Cognition Therapeutics highlights blood test screening efficiencies in Phase 2 Alzheimer's trial
CGTX•Cognition Therapeutics’ partners will present Phase 2 START screening findings at the CTAD conference in Boston on November 19, 2026. Early p-tau217 blood testing identified ineligible participants before amyloid PET scans; the trial is evaluating zervimesine in 545 participants.
1. Screening findings
Cognition Therapeutics’ partners will present Phase 2 START screening findings at the CTAD conference in Boston on November 19, 2026. Early p-tau217 blood testing identified ineligible participants before amyloid PET scans, potentially reducing unnecessary imaging, screening visits and trial-site costs.
2. Trial details
START is evaluating once-daily oral zervimesine against placebo in 545 participants with mild cognitive impairment or early Alzheimer’s disease. Enrollment concluded in the fourth quarter of 2025, and top-line results are expected once the last participants complete 18 months of treatment.




